We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Inverness Medical to Acquire Binax

By Labmedica staff writers
Posted on 17 Feb 2005
In a move to expand the company's technology base, Inverness Medical Innovations, Inc. More...
(Waltham, MA, USA) has agreed to acquire Binax, Inc. (Portland, ME, USA).

Under the terms of the agreement, Inverness will acquire all of the stock of Binax in exchange for 1.4 million shares of its common stock and additional consideration of U.S.$8.6 million in cash at closing. The agreement also provides for additional consideration to Binax shareholders of up to $11 million in cash contingent upon Binax meeting certain new-product development objectives over five years.

Inverness is a leading global supplier of advanced diagnostic devices and is exploring new opportunities for its proprietary electrochemical and other technologies in a variety of applications, including immuno-diagnostics with a focus on women's health, cardiology, and infectious disease. "We expect to benefit from Binax's established reputation in respiratory diagnostics, and we are excited about the potential new-product development opportunities,” said Ron Zwanziger, CEO of Inverness Medical.

Binax is developing rapid diagnostic kits for the identification of pathogens causing infectious diseases. "By leveraging our combined resources and expertise, we expect to be able to improve our ability to deliver significant and innovative new products to point-of-care diagnostic markets,” remarked Roger Piasio, CEO of Binax.





Related Links:
Inverness
Binax

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.